Home / Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival unknow ★ 5.0 · 53 reads Sign in to save this Request CodeZLIB.IO18491037 Published2022 Pages1 LanguageUnknown